Anaphylactic response to factor IX replacement therapy in haemophilia B patients: Complete gene deletions confer the highest risk

Haemophilia

Volumn 5, Issue 2, 1999, Pages 101-105

  Thorland, E C ^a   Drost, J B ^b   Lusher, J M ^c   Warrier, I ^c   Shapiro, A ^d   Koerper, M A ^e   Dimichele, D ^f   Westman, J ^g   Key, N S ^h   Sommer, S S ^a,b  

^a MAYO CLINIC   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^d RILEY HOSPITAL FOR CHILDREN   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f WEILL CORNELL MEDICAL CENTER   (United States)

^g NATIONWIDE CHILDREN S HOSPITAL   (United States)

^h UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

Author keywords

Allergic reaction; Factor IX replacement; Genotype phenotype interactions; Human factor IX mutations; Nonsense mutations; Total gene deletions

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE;

ANAPHYLAXIS; ARTICLE; CLINICAL ARTICLE; GENE DELETION; GENOTYPE; HEMOPHILIA B; HUMAN; IMMUNE RESPONSE; MALE; MISSENSE MUTATION; NONSENSE MUTATION; PRIORITY JOURNAL; RISK;

ANAPHYLAXIS; FACTOR IX; FAMILY HEALTH; FEMALE; GENE DELETION; GENOTYPE; HEMOPHILIA B; HUMANS; LIKELIHOOD FUNCTIONS; MALE; MUTATION; PROBABILITY; RISK FACTORS;

EID: 6544277992     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1999.00303.x     Document Type: Article

References (27)

1. Briët E. Factor IX inhibitors in haemophilia B patients: their incidence and prospects for development with high purity factor IX products. Blood Coagul Fibrinolysis 1991; 2: 47-50.
2. Sultan Y, the French Hemophilia Study Group. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. Thromb Haemost 1992; 67: 600-2.
3. Thompson AR. Molecular biology of the hemophilias. Prog Hemost Thromb 1991; 10: 175-214.
4. Katz J. Prevalence of factor IX inhibitors among patients with haemophilia B - results of a large-scale North American Survey. Haemophilia 1996; 2: 28-31 (Abstract).
5. Giannelli F, Choo KH, Rees PJG, et al. Gene deletions in patients with hemophilia B and antifactor IX antibodies. Nature 1983; 303: 181-2.
6. Matsushita T, Tanimoto M, Yamamoto K, et al. DNA sequence analysis of three inhibitor-positive hemophilia B patients without gross gene deletion: identification of four novel mutations in factor IX gene. J Lab Clin Med 1990; 116: 492-7.
7. Ljung RCR. Gene mutations and inhibitor formation in patients with hemophilia B. Acta Haematol 1995; 94: 49-52.
8. Constantinescu AR, Weiss LS, Saidi P, et al. Nephrotic syndrome associated with hypocomplementemia in a 4-year-old boy with hemophilia B. J Pediatr Hematol Oncol 1997; 19: 345-7.
9. Ewenstein BM, Takemoto C, Warrier I, et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 1997; 89: 1115-16.
10. Shapiro AD, Ragni MV, Lusher JM, et al. Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B. Thromb Haemost 1996; 75: 30-5.
11. Warrier I, Ewenstein BM, Koerper MA, et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 1997; 19: 23-7.
12. Gustafson S, Proper JA, Bowie EJW, et al. Parameters affecting the yield of DNA from human blood. Anal Biochem 1987; 165: 294-9.
13. Koeberl DD, Bottema CDK, Ketterling RP, et al. Mutations causing hemophilia B: direct estimate of the underlying rates of spontaneous germ-line transitions, transversions, and deletions in the human gene. Am J Hum Genet 1990; 47: 202-17.
14. Sommer SS, Sarkar G, et al. Direct sequencing with the aid of phage promoters. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, eds. PCR Protocols: a Guide to Methods and Applications. New York: Academic Press, 1990: 197-205.
15. Ketterling RP, Vielhaber EL, Lind TJ, et al. The rates and patterns of deletions in the human factor IX gene. Am J Hum Genet 1994; 54: 201-13.
16. Yoshitake S, Schach BG, Foster DC, et al. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochem 1985; 24: 3736-50.
17. Bottema CDK, Ketterling RP, Vielhaber E, et al. The pattern of spontaneous germline mutation: relative rates of mutation at or near CpG dinucleotides in the factor IX gene. Hum Genet 1993; 91: 496-503.
18. Eyster ME, Lewis JH, Shapiro SS, et al. The Pennsylvania Hemophilia Program 1973-78. Am J Hematol 1980; 9: 277-86.
19. Bottema CDK, Bottema MJ, Ketterling RP, et al. Why does the human factor IX gene have a G+C content of 40%? Am J Hum Genet 1991; 49: 839-50.
20. Koeberl DD, Bottema CDK, Buerstedde J, et al. Functionally important regions of the factor IX gene have a low rate of polymorphism and a high rate of mutation in the dinucleotide CpG. Am J Hum Genet 1989; 45: 448-57.
21. Kamiya T, Takahashi I, Saito H. Retrospective study of inhibitor formation in Japanese hemophiliacs, Int J Hematol 1995; 62: 175-81.
22. + with inhibitor. Thromb Haemost 1988; 59: 340.
23. Yamamoto K, Takahashi I. DNA analysis in the inhibitor phenotype of the hemophilias. Rinsho Ketsueki 1993; 34: 578-82.
24. Byerley WF. Genetic linkage revisited. Nature 1989; 340: 340-1.
25. Chelly J, Concordet J, Kaplan J, et al. Illegitimate transcription: Transcription of any gene in any cell type. Proc Natl Acad Sci USA 1989; 86: 2617-21.
26. Nordliem M, Sletten K, Husby G, et al. A new prealbumin variant in familial amyloid cardiomyopathy of Danish origin. Scand J Immunol 1988; 27: 119-22.
27. Jacobson DR, Santiago-Schwarz F, Buxbaum JN. Restriction fragment analysis confirms the position 33 mutation in transthyretin from an Israeli patient (SKO) with familiar amyloidotic polyneuropathy. Biochem Biophys Res Commun 1988; 153: 198-202.